Petros Pharmaceuticals, Inc. (PTPI)
OTCMKTS · Delayed Price · Currency is USD
0.005624
-0.000476 (-7.80%)
At close: Jun 2, 2026
Petros Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 4.35 | 5.14 | 1.72 | 13.34 | 9.43 | 23.85 |
Cash & Short-Term Investments | 4.35 | 5.14 | 1.72 | 13.34 | 9.43 | 23.85 |
Cash Growth | -51.27% | 198.88% | -87.11% | 41.49% | -60.47% | 39.14% |
Accounts Receivable | - | - | - | 2.23 | 2.11 | 2.46 |
Other Receivables | - | - | - | - | - | 0.61 |
Receivables | - | - | - | 2.23 | 2.11 | 3.06 |
Inventory | - | - | - | 2.79 | 1.82 | 0.52 |
Prepaid Expenses | 0.04 | 0.03 | 0 | 1.22 | 0.51 | 1.58 |
Other Current Assets | - | - | 5.57 | 0.82 | 0.8 | 1.53 |
Total Current Assets | 4.39 | 5.16 | 7.29 | 20.39 | 14.67 | 30.54 |
Property, Plant & Equipment | - | - | - | 0.26 | 0.4 | 0.52 |
Other Intangible Assets | - | - | - | 8.97 | 12.24 | 25.29 |
Other Long-Term Assets | - | - | 3.34 | 4.18 | 5.11 | 11.03 |
Total Assets | 4.39 | 5.16 | 10.64 | 33.8 | 32.42 | 67.39 |
Accounts Payable | 0.13 | 0.08 | 0.76 | 1.71 | 1.81 | 4.56 |
Accrued Expenses | 0.19 | 0.14 | 0.1 | 1.18 | 1.32 | 3.5 |
Current Portion of Long-Term Debt | - | - | - | 1.16 | 1.09 | - |
Current Portion of Leases | - | - | - | 0.13 | 0.14 | 0.13 |
Other Current Liabilities | 2.3 | 2.07 | 17.16 | 6.59 | 2.71 | 22.8 |
Total Current Liabilities | 2.62 | 2.29 | 18.03 | 10.77 | 7.07 | 30.98 |
Long-Term Debt | - | - | - | 6.86 | 8.39 | - |
Long-Term Leases | - | - | - | 0.14 | 0.26 | 0.41 |
Other Long-Term Liabilities | - | - | 0.08 | 3.55 | 0 | 0.46 |
Total Liabilities | 2.62 | 2.29 | 18.1 | 21.32 | 15.72 | 31.85 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 114.05 | 114.16 | 105.74 | 110.96 | 107.43 | 106.23 |
Retained Earnings | -112.28 | -111.29 | -113.21 | -98.89 | -90.73 | -70.69 |
Total Common Equity | 1.77 | 2.87 | -7.47 | 12.07 | 16.7 | 35.54 |
Shareholders' Equity | 1.77 | 2.87 | -7.47 | 12.48 | 16.7 | 35.54 |
Total Liabilities & Equity | 4.39 | 5.16 | 10.64 | 33.8 | 32.42 | 67.39 |
Total Debt | - | - | - | 8.28 | 9.88 | 0.53 |
Net Cash (Debt) | 4.35 | 5.14 | 1.72 | 5.06 | -0.46 | 23.32 |
Net Cash Growth | -51.27% | 198.88% | -66.04% | - | - | 150.05% |
Net Cash Per Share | 0.11 | 0.18 | 5.35 | 58.14 | -5.51 | 535.30 |
Filing Date Shares Outstanding | 42.37 | 42.37 | 2.14 | 0.28 | 0.08 | 0.08 |
Total Common Shares Outstanding | 42.37 | 42.28 | 0.42 | 0.12 | 0.08 | 0.08 |
Working Capital | 1.77 | 2.87 | -10.73 | 9.62 | 7.6 | -0.44 |
Book Value Per Share | 0.04 | 0.07 | -17.73 | 100.88 | 200.81 | 429.60 |
Tangible Book Value | 1.77 | 2.87 | -7.47 | 3.1 | 4.46 | 10.25 |
Tangible Book Value Per Share | 0.04 | 0.07 | -17.73 | 25.90 | 53.60 | 123.91 |